10mg lyophilized vial
Growth · Research Peptide
Stabilized GHRH analog targeting visceral adiposity.
01 · Overview
Tesamorelin is sermorelin's stronger, longer-acting cousin — a stabilized GHRH analog with a trans-3-hexenoyl group added to prevent enzyme degradation. FDA-approved in 2010 as Egrifta for HIV-associated visceral adiposity, it's the only peptide in the GH-releasing family with a hard label indication for reducing visceral fat.
Off-label it's used by users targeting the same visceral fat compartment — the metabolically dangerous kind that wraps organs — and for the downstream benefits of a higher physiological IGF-1: better sleep, better body composition, and in some studies, improved cognition in older adults.
02 · Fit
Users specifically targeting visceral belly fat and lipid markers, often after a baseline blood panel confirms the issue.
03 · Mechanism
Tesamorelin is a stabilized GHRH analog approved clinically for reducing visceral adipose tissue by increasing endogenous GH and downstream IGF-1.
04 · Use cases
05 · Protocols
Reference protocols paraphrased from published research and common clinical practice. Individual response varies. Work with a qualified provider before running anything below.
Standard visceral fat protocol
Protocol
1mg subcutaneous once daily in the evening
Duration
12–26 weeks — this is a slow-moving change
Notes
The clinical label uses 2mg daily. Many research users start at 1mg for tolerance.
Body composition / recomp
Protocol
1–1.4mg subcutaneous pre-bed
Duration
16 weeks on, 4 weeks off
Notes
Track waist circumference, not just scale weight — the change is visceral, not surface.
Baseline reconstitution
Reconstitute 10mg with 2ml BAC water for 5mg/ml.
06 · Combinations
Common combinations: tesamorelin + AOD-9604 for visceral + surface adipose, tesamorelin + retatrutide for aggressive body composition change, tesamorelin + TB-500 for training recovery during the deficit.
07 · Safety
08 · Trivia
09 · FAQ
Sermorelin is gentler and daily. Tesamorelin is stronger, longer-acting, and specifically evidence-backed for visceral fat. Pick tesamorelin if visceral fat is the target.
Yes — a baseline and one at 8 weeks. Keeping IGF-1 in the upper physiological range is the goal, not exceeding it.
Matches your natural nighttime GH pulse. Also, morning glucose readings stay cleaner if you dose at night.
Educational disclaimer
Everything on this page is for research and educational purposes only. It is not medical advice, a prescription, or a substitute for a conversation with a qualified clinician who knows your full history. Peptides interact with medications, hormones, and existing conditions in ways that require real oversight.